These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 30646185)

  • 1. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.
    Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R
    JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees.
    Wen H; Hockenberry JM
    JAMA Intern Med; 2018 May; 178(5):673-679. PubMed ID: 29610827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing patterns of buprenorphine waivered physicians.
    Thomas CP; Doyle E; Kreiner PW; Jones CM; Dubenitz J; Horan A; Stein BD
    Drug Alcohol Depend; 2017 Dec; 181():213-218. PubMed ID: 29096292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
    Wen H; Hockenberry JM; Borders TF; Druss BG
    Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supply of buprenorphine waivered physicians: the influence of state policies.
    Stein BD; Gordon AJ; Dick AW; Burns RM; Pacula RL; Farmer CM; Leslie DL; Sorbero M
    J Subst Abuse Treat; 2015 Jan; 48(1):104-11. PubMed ID: 25218919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.
    Knudsen HK; Lofwall MR; Havens JR; Walsh SL
    Drug Alcohol Depend; 2015 Dec; 157():36-43. PubMed ID: 26483356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription opioid use patterns, use disorder diagnoses and addiction treatment receipt after the 2014 Medicaid expansion in Oregon.
    Springer R; Marino M; Bailey SR; Angier H; O'Malley JP; Hoopes M; Lindner S; DeVoe JE; Huguet N
    Addiction; 2019 Oct; 114(10):1775-1784. PubMed ID: 31106483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine.
    Andrilla CHA; Coulthard C; Patterson DG
    Am J Prev Med; 2018 Jun; 54(6 Suppl 3):S208-S214. PubMed ID: 29779544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.
    Knudsen HK
    J Stud Alcohol Drugs; 2015 Jul; 76(4):644-54. PubMed ID: 26098042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements.
    Christine PJ; Chahine RA; Kimmel SD; Mack N; Douglas C; Stopka TJ; Calver K; Fanucchi LC; Slavova S; Lofwall M; Feaster DJ; Lyons M; Ezell J; Larochelle MR
    JAMA Netw Open; 2024 Aug; 7(8):e2425999. PubMed ID: 39102264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study.
    Klein TA; Hartung D; Markwardt S
    Subst Abuse Treat Prev Policy; 2022 Jan; 17(1):5. PubMed ID: 35101077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient Limit.
    Luo Q; Erikson CE
    JAMA; 2023 May; 329(20):1792-1794. PubMed ID: 37103912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why aren't physicians prescribing more buprenorphine?
    Huhn AS; Dunn KE
    J Subst Abuse Treat; 2017 Jul; 78():1-7. PubMed ID: 28554597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.